[Pfizer: TLV decision about antilipemic agents is founded on wrong basis].
Brun
Johan
J
Ohlsson-Onerud
Ake
A
Sörensen
Nikolaj
N
D000924:Anticholesteremic Agents / Q000008:administration & dosage / Q000191:economics; D000069059:Atorvastatin; D016265:Conflict of Interest; D016527:Drug Costs; D004345:Drug Industry / Q000191:economics; D016568:Drugs, Generic / Q000191:economics; D006538:Heptanoic Acids / Q000008:administration & dosage / Q000191:economics; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000191:economics; D007356:Insurance, Pharmaceutical Services; D011758:Pyrroles / Q000008:administration & dosage / Q000191:economics; D019821:Simvastatin / Q000008:administration & dosage / Q000191:economics; D013548:Sweden
D000924:Anticholesteremic Agents; D016568:Drugs, Generic; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011758:Pyrroles; D000069059:Atorvastatin; D019821:Simvastatin